Table 4 Simulation 1A subgroup discovery using logistic regression (two subgroups found)
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Single agent | Combination | ASD | |
|---|---|---|---|
Group 1: disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.05\left(-0.30,0.20\right) \) | |||
n = 35 | n = 38 | ||
Age (years) | 64.6 (±5.6) | 65.0 (±5.1) | 0.08 |
Stage 4 | |||
No | 1 (2.9%) | 0 (0.0%) | 0.24 |
Yes | 34 (97.1%) | 38 (100.0%) | 0.24 |
Site | |||
Viscereal | 19 (54.3%) | 15 (39.5%) | 0.3 |
Bone only | 5 (14.3%) | 6 (15.8%) | 0.04 |
Other | 11 (31.4%) | 17 (44.7%) | 0.28 |
Previous treatment | |||
None | 24 (68.6%) | 19 (50.0%) | 0.38 |
Chemo only | 6 (17.1%) | 8 (21.1%) | 0.1 |
Hormonal only | 3 (8.6%) | 4 (10.5%) | 0.07 |
Chemo + hormonal | 2 (5.7%) | 7 (18.4%) | 0.4 |
ECOG score | |||
0 | 15 (42.9%) | 14 (36.8%) | 0.12 |
1 | 20 (57.1%) | 24 (63.2%) | 0.12 |
Disease free >12 months adjuvant to recurrence | |||
Yes | 35 (100.0%) | 38 (100.0%) | 0 |
Group 2: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.35\left(-0.53,0.17\right) \) | |||
n = 65 | n = 62 | ||
Age (years) | 65.2 (±5.9) | 64.9 (±5.0) | 0.06 |
Stage 4 | |||
No | 3 (4.6%) | 1 (1.6%) | 0.17 |
Yes | 62 (95.4%) | 61 (98.4%) | 0.17 |
Site | |||
Visceral | 34 (52.3%) | 34 (54.8%) | 0.05 |
Bone only | 8 (12.3%) | 7 (11.3%) | 0.03 |
Other | 23 (35.4%) | 21 (33.9%) | 0.03 |
Previous treatment | |||
None | 32 (49.2%) | 33 (53.2%) | 0.08 |
Chemo only | 11 (16.9%) | 11 (17.7%) | 0.02 |
Hormonal only | 13 (20.0%) | 15 (24.2%) | 0.1 |
Chemo + hormonal | 9 (13.8%) | 3 (4.8%) | 0.31 |
ECOG score | |||
0 | 30 (46.2%) | 23 (37.1%) | 0.18 |
1 | 35 (53.8%) | 39 (62.9%) | 0.18 |
Disease free >12 months adjuvant to recurrence | |||
No | 65 (100.0%) | 62 (100.0%) | 0 |